FENC - CIK 0001211583
FENNEC PHARMACEUTICALS INC. trades as FENC. In its fiscal 2025 annual report the company posted revenue of $44.64M, down 6.1% from the prior year and net income of -$9.74B. This page tracks FENNEC PHARMACEUTICALS INC. through 792 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin compressed from -9054.5% to -21820.3% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-22 |
| Major company event | 8-K | 2026-05-18 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-14 |
| Quarterly report | 10-Q | 2026-05-14 |
| Insider trade | 4 | 2026-05-12 |
| Insider sale notice | 144 | 2026-05-11 |
| Insider trade | 4 | 2026-05-01 |
The largest companies sharing FENNEC PHARMACEUTICALS INC.'s SEC industry classification (biological products, (no diagnostic substances)).
FENNEC PHARMACEUTICALS INC. reported revenue of $44.64M for fiscal year 2025, a decrease of 6.1% year over year.
In its latest fiscal year FENNEC PHARMACEUTICALS INC. reported a net loss of $9.74B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.